Onfi belongs to the 1,5-benzodiazepine class of drugs and is expected to have a better side-effect profile compared to older 1,4-benzodiazepines. It has been marketed as an anxiolytic since 1975 and an anticonvulsant since 1984. The oral preparation was FDA approved on October 21, 2011. An oral suspension is expected to be available in 2013.
Similar to other benzodiazepines, onfi binds to the interface of the α and γ2-subunit of the GABA-A receptor. However, it is considered a partial agonist to GABA-A receptors which sets onfi apart from 1,4-benzodiazepines which are full agonist. The significance of this difference is that one may experience less sedation with onfi than with other benzodiazepines. Unlike the endogenous GABA ligand, onfi binds allosterically to the GABA receptor to increase the frequency of the chloride channel opening and membrane permeability to chloride ions. Pharmacodynamic tolerance has been demonstrated in animal models.
The most common adverse effects include somnolence, pyrexia, upper respiratory tract infection, and lethargy.
Strength: Belladonna, Canthris, Apis Mellifica, Arnica Monta
Pill Imprint: H 367
View Images & Details